We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Sitagliptin‐associated bullous pemphigoid with autoantibodies against BP230 and laminin‐332.
- Authors
Omori, Reina; Miyagaki, Tomomitsu; Kubo, Marie; Komaki, Reo; Kishi, Arisa; Kuroda, Eri; Okudaira, Azusa; Ohashi, Hiroyuki; Takeuchi, Sora; Koga, Hiroshi; Ishii, Norito; Kadono, Takefumi
- Abstract
Dear Editor, It has been widely known that dipeptidyl peptidase-IV inhibitors (DPP4i) are causative factors of bullous pemphigoid (BP). Anti-laminin-332 antibody usually causes mucous membrane pemphigoid, whereas there have been some conventional pemphigoid cases with anti-laminin-332 antibody showing only skin lesions like our case.5 Although our single case experience cannot make a conclusion, anti-laminin-332 antibody in DPP4i-associated BP might also be associated with an inflammatory phenotype. Anti-BP230 antibody was detected in some DPP4i-associated BP patients in coexistence with the antibody to full-length BP180,4 while only one case of DPP4i-associated BP solely positive for anti-BP230 antibody has been reported.2 That case showed blisters with surrounding erythema similar to our case, suggesting that anti-BP230 antibody might be associated with an inflammatory phenotype in DPP4i-associated BP.
- Subjects
BULLOUS pemphigoid; AUTOANTIBODIES; NICOTINAMIDE
- Publication
International Journal of Dermatology, 2022, Vol 61, Issue 5, pe184
- ISSN
0011-9059
- Publication type
Article
- DOI
10.1111/ijd.15762